SCHEMBL10695877

SCHEMBL10695877

CC(C=O)NCc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SIGMAR1 Q99720 2/20 0.55
▸ ADH1B P00325 1/20 0.50
▸ ADH1C P00326 1/20 0.50
▸ ADH1A P07327 1/20 0.50
▸ ADH7 P40394 1/20 0.50
▸ POLB P06746 1/20 0.47
▸ MEN1 O00255 4/20 0.47
▸ KMT2A Q03164 4/20 0.47
▸ TAAR1 Q96RJ0 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.45
▸ MAPT P10636 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ ACP3 P15309 3/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ BCHE P06276 1/20 0.43
▸ CASR P41180 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7922002 1.00 SIGMAR1 (0.55) SIGMAR1ADH1BADH1CADH1AADH7
SCHEMBL10134832 1.00 SIGMAR1 (0.55) SIGMAR1ADH1BADH1CADH1AADH7
SCHEMBL21193056 0.80 SIGMAR1 (0.55) SIGMAR1ADH1BADH1CADH1AADH7
SCHEMBL6601694 0.78 SIGMAR1 (0.49) SIGMAR1ADH1BADH1CADH1AADH7
SCHEMBL20012288 0.78 SIGMAR1 (0.49) SIGMAR1ADH1BADH1CADH1AADH7
SCHEMBL10696254 0.77 SIGMAR1 (0.61) SIGMAR1ADH1BADH1CADH1AADH7
SCHEMBL9063684 0.77 SIGMAR1 (0.61) SIGMAR1ADH1BADH1CADH1AADH7
SCHEMBL13675822 0.77 SIGMAR1 (0.61) SIGMAR1ADH1BADH1CADH1AADH7
SCHEMBL20012472 0.77 SIGMAR1 (0.47) SIGMAR1ADH1BADH1CADH1AADH7
SCHEMBL29255909 0.77 SIGMAR1 (0.47) SIGMAR1ADH1BADH1CADH1AADH7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8017616-B2 Heterocyclic substituted pyridine compounds with CXCR3 antagonist activity SCHERING CORPORATION (US) 2011-09-13 — — US disclosed
US-20100168124-A1 NOVEL HETEROCYCLIC SUBSTITUTED PYRIDINE COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY SCHERING CORPORATION 2010-07-01 — — US disclosed
EP-0252482-A2 7-Acyloxy-6-aminoacyloxypolyoxylabdanes, process for their preparation and their use as medicine HOECHST AKTIENGESELLSCHAFT (DE) 1988-01-13 — — EP disclosed
EP-0217372-A2 Polyoxygenated labdane derivatives, process for their preparation and their use as medicaments HOECHST AKTIENGESELLSCHAFT (DE) 1987-04-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168124-A1 NOVEL HETEROCYCLIC SUBSTITUTED PYRIDINE COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY CXCR3, CXCR1, CXCL10 SIGMAR1 1961/4885ADH1B 1608/4885ADH1C 2841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback